NYU Study
Validates Use Of Fujirebio Diagnostics' MESOMARK Test For Monitoring
An Asbestos-Linked Cancer (3/12/07)
Results from
a recent study conducted by researchers at New York University
(NYU) School of Medicine show the MESOMARK Assay, the world’s
first and only in vitro test for monitoring mesothelioma
developed by Fujirebio Diagnostics, Inc., is an effective way to
measure proteins within the blood that reflect changes in
disease. The findings represent a major milestone in the
management of mesothelioma, as the test may enable doctors to
more accurately monitor patients for treatment.
More...
PATIENT PROFILES
